Global Needle Free Blood Drawing Devices Market - 2024-2031

Report Overview

The Global Needle Free Blood Drawing Devices Market reached US$ 14.43 billion in 2023 and is expected to reach US$ 26.52 billion by 2031 growing with a CAGR of 7.9% during the forecast period 2024-2031.

Needle-free blood drawing devices offer a painless alternative to conventional blood collection methods that rely on needles and syringes. These devices launch a micro-particle into the skin, creating a tiny opening that allows blood to be extracted using negative pressure. This innovative technique greatly diminishes patient discomfort and lowers the likelihood of needle-stick injuries, a common issue associated with traditional blood collection methods.

The primary benefit of needle-free devices lies in their capacity to alleviate the pain associated with blood draws, addressing a significant concern for numerous patients. These devices significantly diminish the likelihood of needle-stick injuries among healthcare professionals, thereby reducing the risk of transmitting blood-borne pathogens.

Many needle-free devices are crafted to be intuitive and straightforward, making them suitable for use in home environments, which can improve patient adherence to regular health monitoring. These devices frequently utilize cutting-edge technologies, such as micro-particle propulsion or capillary action, to enable blood collection without the need for traditional needles.

Market Dynamics: Drivers

Increasing demand for pain-free alternatives

The demand for the global needle-free blood drawing devices market is driven by multiple factors. One of the primary factors is the increasing demand for pain-free alternatives. The growing preference for needle-free blood drawing devices in the U.S. is largely driven by the desire for less painful medical procedures, particularly among patients who experience anxiety or discomfort with traditional needle-based methods. This trend is significant in hospitals where a high volume of blood draws occurs, impacting clinical decisions and patient care.

Conventional blood collection techniques, like venipuncture, frequently cause considerable pain and anxiety for patients. This discomfort stems from the process of inserting needles into the skin and veins, which can be especially troubling for individuals who have a fear of needles or for those who need to undergo blood draws regularly.

Moreover, key players in the industry more focus on technological advancements that help to propel this market growth. For instance, in April 2022, the Haiim device, developed by Winnoz Technology, represents a significant advancement in blood collection methods by offering a needle-free alternative to traditional venipuncture. This innovative device is designed to collect blood samples from the fingertips, utilizing vacuum-assisted technology to draw between 150 and 500 microliters of whole blood quickly and less painfully.

Also, in February 2022, Tasso, Inc. launched Tasso Care for Prescreening, a comprehensive service solution designed to enhance the prescreening process for clinical trials. This service aims to streamline the recruitment of participants by utilizing Tasso's innovative remote blood collection technology, which is patient-centric and clinically validated.

Restraints

Factors such as the high cost of devices, limited availability of devices, and limited reimbursement policies are expected to hamper the market.

Market Segment Analysis

The global needle-free blood drawing devices market is segmented based on product type, technology, end-user, and region.

The hospital's segment accounted for approximately 65.6% of the global needle-free blood drawing devices market share

The hospital segment is expected to hold the largest market share over the forecast period. The rising frequency of blood draws conducted each year in the U.S. is fueling the demand for needle-free alternatives. In hospitals, numerous patients may require several blood draws each day, and challenges such as difficult venous access often due to obesity, age, or underlying health conditions are increasing the necessity for needle-free solutions. Hospitals play a vital role in the healthcare industry, affecting as much as 70% of clinical decisions, which underscores the importance of effective blood collection methods.

Moreover, key player's product launches & approvals and innovative technological developments are driving this segment's growth in this market. For instance, in November 2023, BD (Becton, Dickinson and Company) launched the PIVO Pro Needle-free Blood Collection Device after receiving 510(k) clearance from the U.S. Food and Drug Administration (FDA). This new device is designed to work with integrated catheters and aims to advance BD's vision of a "One-Stick Hospital Stay."

Similarly, YourBio Health developed the HALO Technology, created by significantly improving the blood collection process by using a patented bladeless microneedle array, which facilitates nearly painless blood draws. Also, in April 2024, the 1st generation TAP (Touch Activated Phlebotomy) device developed by YourBio Health represented a significant breakthrough in blood collection technology. It offered an easy-to-use, virtually painless alternative to traditional blood draws, making it suitable for clinical and remote clinical settings.

Market Geographical Analysis

North America accounted for approximately 46.2% of the global needle-free blood drawing devices market share

North America region is expected to hold the largest market share over the forecast period owing to the increasing demand for pain-free alternatives and a high volume of blood draws that would propel this market growth in the U.S.

Moreover, Approval from regulatory agencies such as the FDA is crucial for the promotion and utilization of needle-free blood drawing devices in the United States. Companies that can secure these approvals, like BD with its PIVO device, are positioned to gain a competitive advantage in the marketplace. In this region, a major number of key players' presence, technological advancements, well-advanced healthcare infrastructure, product launches & approvals, and government initiatives such as awareness programs, partnerships & collaborations are driving this market growth.

For instance, in December 2023, BD (Becton, Dickinson and Company) received 510(k) clearances from the U.S. Food and Drug Administration (FDA) for its new BD MiniDraw Capillary Blood Collection System. This innovative fingertip blood collection device is designed to collect blood samples through a fingerstick, providing a less invasive alternative to traditional venous blood draws. The system allows trained healthcare professionals to obtain lab-quality results from a smaller volume of blood, making it suitable for various common tests.

Also, in October 2022, Catapult Health and Tasso partnered to integrate the Tasso+ self-sampling blood collection device into annual healthcare checkups for employees at major corporations and national health plans in the USA. This collaboration aims to enhance the efficiency and comfort of blood testing during routine health assessments.

Market Segmentation

By Product Type

Handheld Devices

Wearable Devices

By Technology

Venipuncture

Touch-Based

By End-Users

Hospitals

Ambulatory Surgical Centers

Diagnostic Laboratories

Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

U.K.

France

Spain

Italy

Rest of Europe

South America

Brazil

Argentina

The rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the needle-free blood drawing devices market include Becton, Dickinson and Company (BD), YourBio Health, Inc., Tasso, Inc., Romsons, AlphaBiolabs Ltd, Loop Medical SA., Utah Medical Products, Inc., ICU Medical, Inc., and Winnoz Technology, Inc.

Key Developments

In November 2023, BD introduced the PIVO Pro Needle-free Blood Collection Device, which allows blood samples to be drawn directly from a patient's peripheral IV line without using a traditional needle. This innovative device builds upon BD's existing PIVO technology that was first introduced for use with short peripheral IV catheters. The PIVO Pro is designed to be compatible with integrated catheters, including the new Nexiva Closed IV Catheter System with NearPort V Access

In March 2022, Vitestro launched an autonomous blood collection device designed to empower patients by allowing them to participate actively in their blood draw procedures. This innovative venipuncture device utilizes advanced technology, including artificial intelligence and ultrasound-guided imaging, combined with robotic needle insertion, to automate the blood collection process.

Why Purchase the Report?

To visualize the global needle-free blood drawing devices market segmentation based on product type, technology, end-user, and region and understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points of the needle-free blood drawing devices market with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping is available in excel consisting of key products of all the major players.

The global needle-free blood drawing devices market report would provide approximately 59 tables, 50 figures, and 184 pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies